Eli Lilly's retatrutide fails to show statistically significant cardiovascular benefit in secondary endpoints

Clinical data for Eli Lilly's 'triple-G' weight-loss drug, retatrutide, indicates no statistically significant reduction in major adverse cardiovascular events, including death, heart attack, or stroke. The lack of clear cardiovascular benefit complicates the drug's competitive positioning against established GLP-1 therapies that have demonstrated such outcomes.